The observed cooperative effects of blocking MFGE8 and KLK5/7 with COX-2 inhibition in reducing tumor growth provides an important rationale for developing COX-2 inhibitor-based combination therapies for breast cancer patients. This evidence concerns the gene KLK5 and breast cancer.